NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
PR Newswire•24/07/2026•10:13 ET
0
Whiz Insights
Get started
Create a free account to read the full story.